AROVELLA AND IMUGENE COLLABORATION ADVANCES TO NEXT PHASE OF TESTING, page-10

Seriously, Imugene should be shouting this from the rooftops??????
I have written to them today asking for an explanation as to why a similar announcement wasn't released by IMU.

From Arovella's announcement today:

"The collaboration with Imugene opens potential new therapeutic targets for ALA-101 in solid tumours and is an exciting expansion of Arovella’s pipeline.

Imugene’s onCARlytics platform induces solid tumour cells to express CD19 on their surface, allowing them to be targeted by therapies, such as ALA-101, that target cancer cells through CD19.

Solid tumours represent 90% of diagnosed cancer cases. As of 2021, the solid tumour market was valued at US$210 billion.

Arovella’s CEO and MD, Dr Michael Baker, commented: “We are pleased by the first set of data and delighted to continue the partnership with Imugene and its onCARlytics platform.

Combining the two platforms made sense scientifically and seeing this play out in practise is exciting, given the impact this combination of therapeutics could have in solid tumours.”

Imugene’s CEO and MD, Leslie Chong, commented: “The data from the initial studies looks promising. We look forward to capturing the data from the next phase of testing.”